In the present study, gene editing and camouflaging of HER2+ antibody-armed macrophage membranes were utilized to develop a novel targetable biomimetic nanoplatform for targeted delivery of anti-tumor drug GEM, thus achieving the combined therapeutic effect of the HER2+ antibody mediated biotherapy and chemotherapy against HER2+ tumors. This evidence concerns the gene ERBB2 and neoplasm.